BC Extra | Oct 17, 2019
Clinical News

Syros prioritizing oral CDK7, dropping IV after Phase I data

After tolerability issues in a Phase I trial led to lower doses and longer infusion times for its first clinical CDK7 inhibitor, Syros is choosing to concentrate instead on a preclinical oral compound aimed at...
BC Week In Review | Dec 14, 2018
Clinical News

Syros' SY-1425 plus Vidaza leads to 63% ORR in biomarker-positive AML cohort

Syros Pharmaceuticals Inc. (NASDAQ:SYRS) reported Phase II data from a cohort of eight evaluable newly diagnosed, biomarker-positive acute myelogenous leukemia (AML) patients showing that tamibarotene (SY-1425) plus Vidaza azacitidine from Celgene Corp. (NASDAQ:CELG) led to...
BioCentury | Dec 16, 2017
Product Development

Assessing the BCMA scene

Differences in patient populations and a dearth of clinical outcome data mean it’s too soon to declare bluebird bio Inc.’s anti-BCMA chimeric antigen receptor therapy the leader of the pack of CARs that presented clinical...
BC Week In Review | Dec 15, 2017
Clinical News

Syros discontinues single agent tamibarotene

Syros Pharmaceuticals Inc. (NASDAQ:SYRS) said only one of 48 evaluable patients receiving tamibarotene (SY-1425) as monotherapy achieved a complete response in a Phase II trial to treat relapsed or refractory acute myelogenous leukemia (AML) and...
BC Extra | Dec 11, 2017
Clinical News

Syros falls on Phase II AML, MDS data

Syros Pharmaceuticals Inc. (NASDAQ:SYRS) lost $3.92 (32%) to $8.45 on Monday after reporting that only one of 48 evaluable patients receiving tamibarotene (SY-1425) as monotherapy achieved a complete response in a Phase II trial to...
BC Innovations | Oct 26, 2017
Tools & Techniques

Ripe for enhancement

Although still largely the purview of academics, technologies for mapping enhancers to the genes they control are rapidly gaining efficiency and promise to unlock a trove of new targets for drug developers. But companies will...
BC Innovations | Sep 21, 2017
Tools & Techniques

On your marks

With less fanfare than the first two waves, a quiet rise in activity is driving a revival of interest in epigenetics, despite little progress in solving the fundamental challenges that have dogged the field from...
BC Extra | Apr 21, 2017
Financial News

Syros, SteadyMed complete private placements

Cancer company Syros Pharmaceuticals Inc. (NASDAQ:SYRS) and drug delivery play SteadyMed Ltd. (NASDAQ:STDY) raised a total of $65 million in private placements on Friday. Syros raised $35 million through the sale of 2.6 million shares...
BC Innovations | Apr 18, 2017
Distillery Therapeutics

Neurology

INDICATION: Stroke Mouse studies suggest promoting MSR-1 expression could help treat ischemic stroke. MSR-1 levels were higher in brain-derived myeloid cells from a mouse model of ischemic stroke than cells from normal mice. In the...
BC Week In Review | Oct 3, 2016
Clinical News

Tamibarotene: Phase II started

Syros began an open-label, U.S. Phase II trial evaluating 3 mg/m 2 oral tamibarotene twice daily in 28-day cycles in about 40 patients with a biomarker associated with the RARA pathway. Syros has exclusive rights...
Items per page:
1 - 10 of 39